Friday, February 4, 2011
Inspiration Pharmaceuticals Inc., of Laguna Niguel, Calif., said results from the Phase I portion of an ongoing IB1001 study demonstrated noninferiority of the drug in achieving overall levels of replacement factor compared to BeneFIX, an approved recombinant FIX product for hemophilia B marketed by New York-based Pfizer Inc. Those data were presented at the European Association for Haemophilia and Allied Disorders meeting in Geneva.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.